A phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results
- Cohen, E.E.W.
- Harrington, K.J.
- Hong, D.S.
- Mesia, R.
- Brana, I.
- Perez Segura, P.
- Wise-Draper, T.
- Scott, M.L.
- Mitchell, P.D.
- Mugundu, G.M.
- McCoon, P.
- Cook, C.E.
- Mehta, M.
- Keilholz, U.
Aldizkaria:
Annals of oncology : official journal of the European Society for Medical Oncology
ISSN: 1569-8041
Argitalpen urtea: 2018
Alea: 29
Orrialdeak: viii372
Mota: Artikulua